Excelsior Medical Co., Ltd. (TPE:4104)
70.30
-0.90 (-1.26%)
Nov 19, 2026, 1:30 PM CST
Excelsior Medical Revenue
Excelsior Medical had revenue of 2.75B TWD in the quarter ending September 30, 2026, with 25.38% growth. This brings the company's total for the last twelve months to 9.76B, up 11.05% year-over-year. In the year 2025, Excelsior Medical had annual revenue of 8.79B with 2.94% growth. That makes Excelsior Medical the 14,657th largest company in the world by revenue and 477th in Taiwan.
Revenue (ttm)
9.76B
Revenue Growth
+11.05%
P/S Ratio
1.36
Revenue / Employee
70.71M
Employees
138
Market Cap
13.24B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Excelsior Medical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.79B | 250.69M | 2.94% |
| Dec 31, 2024 | 8.54B | 305.14M | 3.71% |
| Dec 31, 2023 | 8.23B | 1.05B | 14.56% |
| Dec 31, 2022 | 7.19B | 613.68M | 9.34% |
| Dec 31, 2021 | 6.57B | -102.34M | -1.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 24.62B |
| Synmosa Biopharma | 7.39B |
| TaiDoc Technology | 4.32B |
| Ever Supreme Bio Technology | 1.14B |
| Medigen Vaccine Biologics | 858.93M |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 41.83M |
| Lumosa Therapeutics | 32.01M |